We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
RNAC

Price
9.76
Stock movement down
-0.11 (-0.99%)
Company name
Cartesian Therapeutics Inc.
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
284.98M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-25.24%
3 year return
-46.90%
5 year return
-32.31%
10 year return
-
Last updated: 2025-09-15

DIVIDENDS

RNAC does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

FINANCIALS

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open10.93
Daily high11.44
Daily low10.92
Daily Volume50K
All-time high789.90
1y analyst estimate36.43
Beta0.83
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
RNACS&P500
Current price drop from All-time high-98.61%-1.46%
Highest price drop-98.89%-56.47%
Date of highest drop27 May 20259 Mar 2009
Avg drop from high-78.84%-10.99%
Avg time to new high115 days12 days
Max time to new high2196 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
RNAC (Cartesian Therapeutics Inc.) company logo
Marketcap
284.98M
Marketcap category
Small-cap
Description
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.
Employees
66
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...